Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5‐fluorouracil therapy
JH Beumer, E Chu, C Allegra… - Clinical …, 2019 - Wiley Online Library
5‐Fluorouracil (5‐FU) is dosed by body surface area, a practice unable to reduce the
interindividual variability in exposure. Endorsed by the International Association of …
interindividual variability in exposure. Endorsed by the International Association of …
The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study
B Yoshimura, Y Yada, R So, M Takaki, N Yamada - Psychiatry research, 2017 - Elsevier
Previous studies have suggested that a delay in initiating clozapine is one of the predictors
of outcomes in treatment-resistant schizophrenia (TRS). However, whether there is a critical …
of outcomes in treatment-resistant schizophrenia (TRS). However, whether there is a critical …
Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics
E Spina, C Hiemke, J de Leon - Expert opinion on drug metabolism …, 2016 - Taylor & Francis
ABSTRACT Introduction: Second-generation antipsychotics (SGAs) are frequently co-
prescribed with drug metabolic inducers and inhibitors. SGA pharmacokinetic drug-drug …
prescribed with drug metabolic inducers and inhibitors. SGA pharmacokinetic drug-drug …
Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective
M Dold, S Leucht - BMJ Ment Health, 2014 - mentalhealth.bmj.com
A significant number of patients with schizophrenia do not respond adequately to an initial
antipsychotic trial. As first step within a treatment algorithm for therapy-refractory …
antipsychotic trial. As first step within a treatment algorithm for therapy-refractory …
Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia
Objective Treatment resistance is a challenge for the management of schizophrenia. It is not
always clear whether inadequate response is secondary to medication ineffectiveness, as …
always clear whether inadequate response is secondary to medication ineffectiveness, as …
Seizure associated with clozapine: incidence, etiology, and management
AM Williams, SH Park - CNS drugs, 2015 - Springer
Seizures are a known adverse effect of clozapine therapy. The literature varies on incidence
rates of seizures, secondary to varying time frames in which each seizure occurred. Tonic …
rates of seizures, secondary to varying time frames in which each seizure occurred. Tonic …
Sensitive determination of Fluoxetine and Citalopram antidepressants in urine and wastewater samples by liquid chromatography coupled with photodiode array …
A new analyte separation and preconcentration method for the trace determination of
antidepressant drugs, Fluoxetine (FLU) and Citalopram (CIT) in urine and wastewaters, was …
antidepressant drugs, Fluoxetine (FLU) and Citalopram (CIT) in urine and wastewaters, was …
Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine
Epigenetic processes, such as DNA methylation, and molecular chaperones, including
FK506-binding protein 51 (FKBP51), are independently implicated in stress-related mental …
FK506-binding protein 51 (FKBP51), are independently implicated in stress-related mental …
Classification of advanced stages of Parkinson's disease: translation into stratified treatments
Advanced stages of Parkinson's disease (advPD) still impose a challenge in terms of
classification and related stage-adapted treatment recommendations. Previous concepts …
classification and related stage-adapted treatment recommendations. Previous concepts …
Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis
EL Carlson, V Karuppagounder, WJ Pinamont… - Science Translational …, 2021 - science.org
Osteoarthritis (OA) is a debilitating joint disease characterized by progressive cartilage
degeneration, with no available disease-modifying therapy. OA is driven by pathological …
degeneration, with no available disease-modifying therapy. OA is driven by pathological …